Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 102,619 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 102,619 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at $96,632,794.28. The trade was a 15.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Thursday, November 5th, Daniel O’Day sold 9,810 shares of Gilead Sciences stock. The shares were sold at an average price of $175.17, for a total transaction of $1,718,417.70.
• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total transaction of $2,546,100.00.
• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Trading Down 0.4%

GILD stock opened at $166.89 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The firm’s 50-day simple moving average is $153.04 and its 200 day simple moving average is $140.94. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. Gilead Sciences’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.47 earnings per share. Analysts predict that Gilead Sciences, Inc. will post -1.07 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Cornerstone Advisory LLC bought a new stake in Gilead Sciences during the 3rd quarter valued at approximately $214,000. Aberdeen Group plc grew its position in Gilead Sciences by 3.1% during the 3rd quarter. Aberdeen Group plc now owns 1,034,855 shares of the biopharmaceutical company’s stock worth $154,245,000 after purchasing an additional 31,340 shares during the last quarter. Compass Capital Management Inc. purchased a new stake in Gilead Sciences in the third quarter valued at $245,000. Valmark Advisers Inc. raised its holdings in Gilead Sciences by 4.0% in the 3rd quarter. Valmark Advisers Inc. now owns 3,391 shares of the biopharmaceutical company’s stock worth $505,000 after purchasing an additional 130 shares during the period. Finally, Allworth Financial LP boosted its stake in Gilead Sciences by 6.4% during the 3rd quarter. Allworth Financial LP now owns 50,207 shares of the biopharmaceutical company’s stock worth $7,483,000 after purchasing an additional 3,015 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HSBC boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. TD Cowen increased their target price on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Truist Financial lifted their price objective on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.15.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.